Purpose Etrasimod, an oral sphingosine-1-phosphate receptor modulator, demonstrated efficacy and safety in pivotal phase 3 trials for moderate-to-severe ulcerative colitis (UC). This study aimed to evaluate the real-world effectiveness, safety, and treatment persistence of etrasimod ...
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/dcfc506d-7c52-4e61-8e2c-132e2c4ff1bf)